Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412750 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)
A Phase 3 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 159
- Enrollment target
NCT00412750 is a Phase 3 study that was terminated before completion, run by Novartis. The registered enrollment target is 159 participants.
The verdict
NCT00412750, a Phase 3 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 159 participants
- Enrollment target
Study Summary
To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.
Interventions
- DRUG Telbivudine (LdT)
- DRUG peginterferon alpha-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412750
The ClinicalTrials.gov registry entry for NCT00412750 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Telbivudine (LdT) is the first listed.
NCT00412750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412750 about?
NCT00412750 is a clinical study titled "Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)". To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.
What is the current status of trial NCT00412750?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 159 participants. The study started on 2006-12. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00412750?
The interventions under investigation include: Telbivudine (LdT) (DRUG), peginterferon alpha-2a (DRUG).
Who is sponsoring clinical trial NCT00412750?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.